Investors might want to bet on Supernus Pharmaceuticals (SUPN) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracke ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's diseaseONAPGO is a wearable subcutaneous infusion device that provides continuous treatment during the waking day for more consistent control of OFF timeONAPGO will be available in the U.S. in second quarter 2025 ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and com ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous infusion device that provides continuous treatment during the waking day for more consistent control of OFF timeONAPGO will be available in the U.S. in second quarter 2025 ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and co ...

Updated label includes new data in Section 12.2, detailing serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition, highlighting Qelbree’s multimodal pharmacodynamicsQelbree is the first ADHD treatment to meet its post marketing requirement and receive labeling approval following the 2019 FDA guidance on Clinical Lactation Studies1 ROCKVILLE, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing an ...

MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for Qelbree® (viloxazine extended-release capsules) has been accepted for review by Health Canada. Qelbree® is a novel nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Knight entered into an agreement in December 2023 with Supernus Pharmaceuticals, Inc. (NASDAQ: ...

ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 12:00 p.m. ET at the Lotte New York Palace in New York City. Inve ...

ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 9:30 a.m. GMT (4:30 a.m. EST) at the Waldorf Hilton in London, United Kingdo ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we are circling back to a small biopharma concern called Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) . We looked at this name in the first quarter of this year and noted ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Peter Vozzo – Investor Relations-ICR Healthcare Jack Khattar – Chief Executive Officer Tim Dec – Chief Financial Officer Conference Call Participants Andrew Tsai – Jefferies Stacy Ku – TD Cowen David Amsellem – Piper Sandler Operator Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in lis ...

For the quarter ended September 2024, Supernus Pharmaceuticals (SUPN) reported revenue of $175.69 million, up 14.2% over the same period last year. EPS came in at $1.06, compared to -$0.29 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $155.06 million, representing a surprise of +13.30%. The company delivered an EPS surprise of +171.79%, with the consensus EPS estimate being $0.39.While investors closely watch year-over-year changes in headline numbers -- revenue an ...